This report was first published by Endpoints News. To see the original version, click here
The Biosecure Act has another chance in Congress after the Senate passed a new version this week. But the latest iteration stops short of targeting WuXi AppTec and WuXi Biologics, key fixtures in US drugmakers’ supply chains.
The Senate voted on Thursday to attach Biosecure as an amendment to the annual defense policy bill. It seeks to curb US biotechs’ reliance on Chinese suppliers over national security concerns.
您已閱讀20%（507字），剩余80%（1987字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。